Select company
- Ticker/CompanyMarket Cap.
No results found
Select metric
Pick a metric...
$ 38.51MWorking Capital
VS
Market
Sector
Industry
History
$ 0.39Close
$ 0.29 - $ 4.28 52-Week Range
Ticker Information
Ticker
VYNECompany Name
VYNE THERAPEUTICS INCSector
HealthcareIndustry
BiotechnologyExchange
NASDAQVYNE THERAPEUTICS INC - Working Capital Chart Analysis (TTM)
From
Zoom
1Y
3Y
5Y
10Y
VYNE - Working Capital Historical data
| Date | Current Assets | Current Liabilities | Working Capital |
|---|---|---|---|
| 6/30/2025 | $ 44.34M | $ 5.84M | $ 38.51M |
| 3/31/2025 | $ 54.91M | $ 12.29M | $ 42.62M |
| 12/31/2024 | $ 64.44M | $ 14.82M | $ 49.62M |
| 9/30/2024 | $ 73.53M | $ 12.66M | $ 60.87M |
| 6/30/2024 | $ 83.78M | $ 11.75M | $ 72.02M |
| 3/31/2024 | $ 90.22M | $ 6.93M | $ 83.29M |
| 12/31/2023 | $ 95.96M | $ 7.54M | $ 88.42M |
| 9/30/2023 | $ 17.51M | $ 6.45M | $ 11.06M |
| 6/30/2023 | $ 22.96M | $ 6.37M | $ 16.59M |
| 3/31/2023 | $ 33.02M | $ 7.52M | $ 25.5M |
Key Performance Insights, Last 5 Years
- VYNE THERAPEUTICS INC's latest trailing twelve months (TTM) Working Capital stands at $ 74.97M.
- Over the past 5 years, VYNE THERAPEUTICS INC's average Working Capital has been $ 54.24M.
- The median Working Capital for VYNE THERAPEUTICS INC during this period was $ 50.84M
- VYNE THERAPEUTICS INC reached its highest Working Capital over the past 5 years at $ 121.57M.
- The lowest Working Capital recorded by VYNE THERAPEUTICS INC in the same timeframe $ 11.06M
VYNE THERAPEUTICS INC's Working Capital vs. competitors
We picked the following companies as peers based on multiple factors, including sector, industry, market capitalization and revenue
Working Capital Benchmarks
Similar metrics to Working Capital:
- Current Ratio - [Calculation] The current ratio is a liquidity indicator that describes the company’s ability to pay short-term obligations due within one year. Calculated by dividing current assets [AssetsC] by current liabilities [LiabilitiesC].
- Quick Ratio - [Calculation] The quick ratio is a liquidity indicator that describes the company’s ability to pay short-term obligations without the need to sell its inventory or receive additional financing. Calculated by dividing current assets [AssetsC] minus [Inventory] by current liabilities [LiabilitiesC].
- Current Liabilities - [Balance Sheet] The current (short-term) portion of [Liabilities] includes obligations that are due to be paid to creditors within one year, reported if the company operates a classified balance sheet that segments current and non-current [Liabilities]
- Total Liabilities - [Balance Sheet] Total liabilities are the sum of all possible claims against the company. Common examples are [Debt], [Payables], deferred revenues, issued bonds, warranties, and tax liabilities.
- Non-Current Liabilities - [Balance Sheet] The non-current (long-term) portion of [Liabilities] includes obligations that are due to be paid to creditors more than year in the future, reported if the company operates a classified balance sheet that segments current and non-current [Liabilities]
Definition of Working Capital
[Calculation] The working capital represents the capital used in day-to-day operations. It is the difference between a company’s short-term assets [AssetsC] and current liabilities [LiabilitiesC].AssetsC - LiabilitesC
(=) Working Capital Working Capital for VYNE THERAPEUTICS INC is calculated as follows: AssetsC [ $ 98.16M ] - LiabilitesC [ $ 23.19M ]
(=) Working Capital [ $ 74.97M ] VYNE - Working Capital, Last 5 years
$ 11.06M
Minimum
Sep 30, 2023
$ 121.57M
Maximum
Mar 31, 2021
$ 54.24M
Average
$ 50.84M
Median
Working Capital Benchmark AnalysisMarket
The chart above depicts the distribution of Working Capital for companies in the Total Stock Market. The average Working Capital of the companies is $ 96.5M with a standard deviation of $ 173.86M.
The following table provides additional summary stats:
Working Capital in the Market:
| filtered constituents | 2.78K |
|---|---|
| min | $ -465.2M |
| max | $ 607.04M |
| average | $ 96.5M |
| median | $ 32.21M |
| std | $ 173.86M |